Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 0p-1-2
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Lung transplantation (TxP) is now a validated treatment of end-stage pulmonary diseases, but
long-term graft and patient survival are still hampered by the development of chronic
allograft dysfunction (CLAD) affecting > 50% of patients.
The investigators propose to conduct a phase III clinical randomized trial that will assess
the efficacy of Nintedanib to hamper the lung decline in LTx recipients with BOS. This is the
first trial testing this molecule in lung Tx recipients. If case of demonstrated
effectiveness of Nintedanib, the benefit for lung transplant patients carrying a BO is high
in terms of stabilization of lung function and enhancement of survival.